ArticleCholesterol2013
Current views on genetics and epigenetics of cholesterol gallstone disease.
Article in Cholesterol, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Modified dietary fat intake for treatment of gallstone disease in people of any age.The Cochrane database of systematic reviews · 2024Pooled it
- Bempedoic acid within the phase ternary diagram governing biliary cholesterol solubilization and gallstone risk.Journal of lipid research · 2026Review
- Review
- Pathophysiology and Treatment of Lipid Abnormalities in Cerebrotendinous Xanthomatosis: An Integrative Review.Brain sciences · 2023Review
- Human Hepatocyte Nuclear Factors (HNF1 and LXRb) Regulate CYP7A1 in HIV-Infected Black South African Women with Gallstone Disease: A Preliminary Study.Life (Basel, Switzerland) · 2023Article
- Effect and related mechanism of Yinchenhao decoction on mice with lithogenic diet-induced cholelithiasis.Experimental and therapeutic medicine · 2021Article
- Transcriptomic profiles reveal differences in zinc metabolism, inflammation, and tight junction proteins in duodenum from cholesterol gallstone subjects.Scientific reports · 2020Article
- Cholecystectomy and risk of metabolic syndrome.European journal of internal medicine · 2018Review
- An update on the pathogenesis of cholesterol gallstone disease.Current opinion in gastroenterology · 2018Review
- Recent advances in understanding and managing cholesterol gallstones.F1000Research · 2018Review
- Cholecystectomy: a way forward and back to metabolic syndrome?Laboratory investigation; a journal of technical methods and pathology · 2018Article
- Preventing a Mass Disease: The Case of Gallstones Disease: Role and Competence for Family Physicians.Korean journal of family medicine · 2016Review
- Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers.International journal of molecular sciences · 2016Review
- Revisiting Human Cholesterol Synthesis and Absorption: The Reciprocity Paradigm and its Key Regulators.Lipids · 2016Review
- Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.American journal of physiology. Gastrointestinal and liver physiology · 2015Article
- Association of caveolin-3 and cholecystokinin A receptor with cholesterol gallstone disease in mice.World journal of gastroenterology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholesterol gallstone disease, one of the commonest digestive diseases in western countries, is induced by an imbalance in cholesterol metabolism, which involves intestinal absorption, hepatic biosynthesis, and biliary output of cholesterol, and its conversion to bile acids. Several components of the metabolic syndrome (e.g., obesity, type 2 diabetes, dyslipidemia, and hyperinsulinemia) are also well-known risk factors for gallstones, suggesting the existence of interplay between common pathophysiological pathways influenced by insulin resistance, genetic, epigenetic, and environmental factors. Cholesterol gallstones may be enhanced, at least in part, by the abnormal expression of a set of the genes that affect cholesterol homeostasis and lead to insulin resistance. Additionally, epigenetic mechanisms (mainly DNA methylation, histone acetylation/deacetylation, and noncoding microRNAs) may modify gene expression in the absence of an altered DNA sequence, in response to different lithogenic environmental stimuli, such as diet, lifestyle, pollutants, also occurring in utero before birth. In this review, we will comment on various steps of the pathogenesis of cholesterol gallstones and interaction between environmental and genetic factors. The epigenomic approach may offer new options for therapy of gallstones and better possibilities for primary prevention in subjects at risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.